<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7256510\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="as the COVID-19 resource centre remains active. Highlights â€¢Novel coronavirus" exact="disease" post="(COVID-19) is a global issue nowadays. â€¢COVID-19 is caused"/>
  <result pre="is a global issue nowadays. â€¢COVID-19 is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). â€¢The current knowledge about"/>
  <result pre="a global issue nowadays. â€¢COVID-19 is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). â€¢The current knowledge about the"/>
  <result pre="global issue nowadays. â€¢COVID-19 is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). â€¢The current knowledge about the treatment"/>
  <result pre="best way of controlling the pandemic. Abstract The novel coronavirus" exact="disease" post="(COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus"/>
  <result pre="Abstract The novel coronavirus disease (COVID-19) pandemic, caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge."/>
  <result pre="The novel coronavirus disease (COVID-19) pandemic, caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite"/>
  <result pre="novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense"/>
  <result pre="effective vaccine and viable treatment options have eluded investigators. Therefore," exact="infection" post="prevention, early viral detection and identification of successful treatment"/>
  <result pre="viable treatment options have eluded investigators. Therefore, infection prevention, early" exact="viral" post="detection and identification of successful treatment protocols provide the"/>
  <result pre="of successful treatment protocols provide the best approach in controlling" exact="disease" post="spread. In this review, current therapeutic options, preventive methods"/>
  <result pre="international preventive action was taken. Finally, after several cases of" exact="pneumonia" post="with an unfamiliar etiology were observed at the end"/>
  <result pre="Health Organization (WHO), but it was then renamed as â€œsevere" exact="acute" post="respiratory syndrome coronavirus 2â€� (SARS-CoV-2) by the international committee"/>
  <result pre="Organization (WHO), but it was then renamed as â€œsevere acute" exact="respiratory" post="syndrome coronavirus 2â€� (SARS-CoV-2) by the international committee of"/>
  <result pre="(WHO), but it was then renamed as â€œsevere acute respiratory" exact="syndrome" post="coronavirus 2â€� (SARS-CoV-2) by the international committee of the"/>
  <result pre="international committee of the Coronavirus Study Group (CSG), and the" exact="disease" post="called â€œcoronavirus disease 2019â€� (COVID-19) by WHO [3]. It"/>
  <result pre="the Coronavirus Study Group (CSG), and the disease called â€œcoronavirus" exact="disease" post="2019â€� (COVID-19) by WHO [3]. It is thought that"/>
  <result pre="of this virus through coughing, sneezing, and the spread of" exact="respiratory" post="droplets or aerosols was accepted. In addition, almost all"/>
  <result pre="addition, almost all countries in continents throughout the world reported" exact="disease" post="spread caused by aerosol penetration into the upper the"/>
  <result pre="world reported disease spread caused by aerosol penetration into the" exact="upper" post="the respiratory tract and lungs via inhalation [4], [5]."/>
  <result pre="disease spread caused by aerosol penetration into the upper the" exact="respiratory" post="tract and lungs via inhalation [4], [5]. There followed"/>
  <result pre="world. A mathematical model examined whether the control of SARS-CoV-2" exact="infection" post="could be achieved by isolating affected patients, and tracking"/>
  <result pre="were smuggled from Malaysia to China, along with other possible" exact="intermediate" post="hosts like turtles or snakes could be the direct"/>
  <result pre="fever, dry cough, tachypnea, and shortness of breath [15]. Although" exact="diarrhea" post="was present in about 20â€&quot;25% of patients with MERS-CoV"/>
  <result pre="rarely seen in patients with COVID-19. In another study, confusion," exact="chest" post="pain, vomiting, and nausea were also reported as COVID-19"/>
  <result pre="on the skin, or discoloration of fingers or toes, and" exact="viral conjunctivitis." post="Some laboratory studies have shown the occurrence of cytokine"/>
  <result pre="opacity in the lungs [19]. Moreover, SARS-CoV-2 can affect the" exact="cardiovascular" post="system [16], gastrointestinal tract [20], and can cause acute"/>
  <result pre="the cardiovascular system [16], gastrointestinal tract [20], and can cause" exact="acute" post="kidney failure [2], [19]. Moreover, evaluation of liver manifestations"/>
  <result pre="cardiovascular system [16], gastrointestinal tract [20], and can cause acute" exact="kidney failure" post="[2], [19]. Moreover, evaluation of liver manifestations in 148"/>
  <result pre="and can cause acute kidney failure [2], [19]. Moreover, evaluation" exact="of liver" post="manifestations in 148 patients with COVID-19 indicated that more"/>
  <result pre="and developing new sensitive diagnostic approaches and therapeutic options. 4" exact="Infection" post="in children Unlike adults, children with COVID-19 have milder"/>
  <result pre="at the highest risk of the severe form of the" exact="disease" post="[23]. Although early studies showed that children with COVID-19"/>
  <result pre="had underlying conditions. By March 8th, 2020, one child with" exact="intussusception" post="had died, 21 children remained in a stable condition"/>
  <result pre="child with intussusception had died, 21 children remained in a" exact="stable" post="condition in the ward, and 149 cases were discharged"/>
  <result pre="young infants who were diagnosed with COVID-19, also had classic" exact="Kawasaki disease" post="(KD) or a KD-like disease, which indicates that more"/>
  <result pre="infants who were diagnosed with COVID-19, also had classic Kawasaki" exact="disease" post="(KD) or a KD-like disease, which indicates that more"/>
  <result pre="protective equipment (PPE) could also be the source of airborne" exact="infections" post="[27]. As mentioned before, person-to-person spread of SARS-CoV-2 is"/>
  <result pre="person-to-person spread of SARS-CoV-2 is supposed to occur mainly via" exact="respiratory" post="droplets, when a patient coughs, sneezes, or even talks"/>
  <result pre="(almost two meters) and remain in the air for a" exact="limited" post="time. However, SARS-CoV-2 remains intact and contagious in droplets"/>
  <result pre="is recommended. The reported contagion rates from a patient with" exact="symptomatic" post="infection vary by location and efficiency of infection control"/>
  <result pre="recommended. The reported contagion rates from a patient with symptomatic" exact="infection" post="vary by location and efficiency of infection control measures."/>
  <result pre="patient with symptomatic infection vary by location and efficiency of" exact="infection" post="control measures. Based on a joint WHO-China report, the"/>
  <result pre="measures. Based on a joint WHO-China report, the rate of" exact="secondary" post="COVID-19 infection ranged from one to five percent among"/>
  <result pre="on a joint WHO-China report, the rate of secondary COVID-19" exact="infection" post="ranged from one to five percent among tens of"/>
  <result pre="from 5 to 13Â days after being discharged [34]. Also," exact="viral" post="shedding in the stool likely occurs up for to"/>
  <result pre="of death) with a mean of 11.2Â days after the" exact="respiratory" post="tract test was negative [36]. So, because SARS-CoV-2 can"/>
  <result pre="negative results in at least a 24Â h interval; (2)" exact="Complete" post="resolution of the patient's acute exudative pulmonary lesions on"/>
  <result pre="a 24Â h interval; (2) Complete resolution of the patient's" exact="acute" post="exudative pulmonary lesions on chest Computed Tomography (CT) examination;"/>
  <result pre="24Â h interval; (2) Complete resolution of the patient's acute" exact="exudative" post="pulmonary lesions on chest Computed Tomography (CT) examination; (3)"/>
  <result pre="h interval; (2) Complete resolution of the patient's acute exudative" exact="pulmonary" post="lesions on chest Computed Tomography (CT) examination; (3) Normalization"/>
  <result pre="Complete resolution of the patient's acute exudative pulmonary lesions on" exact="chest" post="Computed Tomography (CT) examination; (3) Normalization of temperature for"/>
  <result pre="for over 72Â h; and (4) Resolution of the patient's" exact="respiratory" post="symptoms [34], [37]. Although SARS-CoV-2 RNA has been discovered"/>
  <result pre="appear to be an important factor in the spread of" exact="infection" post="[30]. It should be mentioned that a study of"/>
  <result pre="was reported to test negative for seven duplicate samples of" exact="neonatal" post="blood, stool, and oropharynx [41]; however, recent studies showed"/>
  <result pre="relatively long incubation period, presence of asymptomatic patients, and continued" exact="viral" post="shedding after recovery all underline the importance of home"/>
  <result pre="government carried out [47]. 6 Temperature and humidity and SARS-CoV-2" exact="infection" post="One study investigated the relationship between the mean daily"/>
  <result pre="COVID-19 [52]. It is possible to minimize the spread of" exact="infection" post="by making the following recommendations. Staying at home (home"/>
  <result pre="Also, sterilizing the used respirator, only reusing it for a" exact="limited" post="time, and proper disposal of the used masks, have"/>
  <result pre="as single-use items, they could be used again for a" exact="limited" post="time unless there is a risk for contamination through"/>
  <result pre="there is a risk for contamination through the deposition of" exact="infectious" post="particles on the surface [54]. When the respirator becomes"/>
  <result pre="of hands is the best way to protect against SARS-CoV-2" exact="infection" post="[55]. A study in six departments of a hospital"/>
  <result pre="by doctors and nurses were effective in preventing against COVID-19" exact="infection" post="[56]. In terms of vaccines, there are a large"/>
  <result pre="SARS-CoV, MERS-CoV being tested in animals, including a live-attenuated virus," exact="viral" post="vectors, inactivated virus, subunit vaccines, recombinant DNA, and proteins"/>
  <result pre="SARS-CoV-2. 8 COVID-19 therapeutic options Huang et al.[57] reported that" exact="acute" post="respiratory distress syndrome (ARDS) was the most common complication"/>
  <result pre="8 COVID-19 therapeutic options Huang et al.[57] reported that acute" exact="respiratory" post="distress syndrome (ARDS) was the most common complication in"/>
  <result pre="therapeutic options Huang et al.[57] reported that acute respiratory distress" exact="syndrome" post="(ARDS) was the most common complication in COVID-19 patients"/>
  <result pre="most common complication in COVID-19 patients [58], followed by anemia," exact="acute" post="cardiac injury, and secondary infections. Hence, empirical antibiotics, antiviral"/>
  <result pre="COVID-19 patients [58], followed by anemia, acute cardiac injury, and" exact="secondary" post="infections. Hence, empirical antibiotics, antiviral drugs, and systemic corticosteroids"/>
  <result pre="injury, and secondary infections. Hence, empirical antibiotics, antiviral drugs, and" exact="systemic" post="corticosteroids are used as treatments [59]. Moreover, Holshue et"/>
  <result pre="with intractable hypoxemia. So, the treatments of patients with COVID-19" exact="infection" post="are mainly symptomatic in nature. It should be mentioned"/>
  <result pre="So, the treatments of patients with COVID-19 infection are mainly" exact="symptomatic" post="in nature. It should be mentioned that the panel"/>
  <result pre="such as Lopinavir/Ritonavir or otherÂ protease inhibitors (used for human" exact="immunodeficiency" post="virus (HIV)) because of unfavorable pharmacodynamics and negative clinical"/>
  <result pre="(e.g., Baricitinib [62]) because of their broad immunosuppressive effects, and" exact="systemic" post="corticosteroids during the treatment of mechanically ventilated patients with"/>
  <result pre="around the world. 8.1 Virally targeted agents Antiviral drugs and" exact="systemic" post="corticosteroids, including neuraminidase inhibitors (Oseltamivir, Peramivir, and Zanamivir), Ganciclovir,"/>
  <result pre="patients [63], [64], [65], are used in the clinic for" exact="viral" post="infections. However, they have not been shown to have"/>
  <result pre="the RNA-dependent RNA polymerase enzyme and affect the structure of" exact="viral" post="RNA in a large spectrum of RNA viruses, including"/>
  <result pre="the RNA-dependent RNA polymerase of RNA viruses such as Influenza," exact="Yellow fever," post="Chikungunya, Ebola [68], Norovirus, and Enterovirus [67]. Besides, in"/>
  <result pre="8.1.1.3 Ribavirin Ribavirin is a guanine derivative approved for treating" exact="respiratory" post="syncytial virus (RSV) and hepatitis C virus (HCV) infections,"/>
  <result pre="guanine derivative approved for treating respiratory syncytial virus (RSV) and" exact="hepatitis C" post="virus (HCV) infections, which also showed positive results in"/>
  <result pre="with SARS and MERS, but its side effects such as" exact="anemia" post="may be severe at high doses [71]. Besides, its"/>
  <result pre="was initially developed to treat HCV, and its efficacy against" exact="Yellow fever" post="revealed its antiviral activity in preclinical studies against many"/>
  <result pre="including SARS-CoV and MERS-CoV [71]. At present, it is in" exact="primary" post="clinical trials to assess its safety in healthy individuals."/>
  <result pre="previous studies that showed after administration of Lopinavir/Ritonavir, Î²-coronavirus the" exact="viral" post="loads were significantly reduced, and coronavirus titers were low"/>
  <result pre="[82]. 8.1.1.6.3 Disulfiram Disulfiram is a drug used for treating" exact="chronic" post="alcoholism by inducing an acute intolerance to ethanol (drinking"/>
  <result pre="8.1.1.6.3 Disulfiram Disulfiram is a drug used for treating chronic" exact="alcoholism" post="by inducing an acute intolerance to ethanol (drinking alcohol)."/>
  <result pre="a drug used for treating chronic alcoholism by inducing an" exact="acute" post="intolerance to ethanol (drinking alcohol). Disulfiram was reported to"/>
  <result pre="the effects of the virus on the host response to" exact="viral infection." post="In a small clinical trial of 11 COVID-19 patients,"/>
  <result pre="lectin, which binds to oligosaccharides on the surface of various" exact="viral" post="glycoproteins, including HIV glycoprotein 120 and SARS-CoV spike glycoprotein"/>
  <result pre="is an anti-malarial drug [100] with practical activity against SARS-CoV-2" exact="infection" post="[101], which could help in the treatment of COVID-19."/>
  <result pre="effects, such as suppression of the production and release of" exact="tumor" post="necrosis factor-Î± (TNF-Î±), and Interleukin (IL-6). It also works"/>
  <result pre="novel type of autophagy inhibitor [102], which probably interferes with" exact="viral infection" post="and replication. Moreover, scientists have reported in a number"/>
  <result pre="type of autophagy inhibitor [102], which probably interferes with viral" exact="infection" post="and replication. Moreover, scientists have reported in a number"/>
  <result pre="Remdesivir [105], where the percentage of patients with a negative" exact="viral" post="nucleic acid test was higher with anti-malarial drugs. Until"/>
  <result pre="and considering that an overdose of CQ could result in" exact="acute" post="poisoning and death [107]; the safe dosage (6â€&quot;6.5Â mg/kg"/>
  <result pre="toxicity. 8.3 Cytokine-based therapy The cytokine storm or cytokine release" exact="syndrome" post="(CRS) results from the widespread release of pro-inflammatory cytokines"/>
  <result pre="[111], [112], [113]. It has been shown that by activating" exact="type 1" post="macrophages (M1) and T-helper 1 (Th1) cells, COVID-19 increases"/>
  <result pre="TNF-Î±, granulocyte-colony stimulating factor (G-CSF), macrophage inflammatory protein 1AÂ (MIP-1A)," exact="monocyte" post="chemoattractant protein-1 (MCP-1), CXCL-10, IL-10, and IL-7 in severe"/>
  <result pre="severe COVID-19 patients indicates the importance of CRS in the" exact="disease" post="progression [16]. So, CRS is considered to be a"/>
  <result pre="Corticosteroids can be useful in controlling CRS, for instance in" exact="cancer" post="immunotherapy. Initially, dexamethasone was proposed as an effective agent"/>
  <result pre="for managing CRS. However, due to the enhanced risk of" exact="vascular" post="necrosis and diabetes (which are mortality risk factors for"/>
  <result pre="However, due to the enhanced risk of vascular necrosis and" exact="diabetes" post="(which are mortality risk factors for COVID-19), corticosteroid administration"/>
  <result pre="decrease the release of interferon-gamma, and to treat CRS and" exact="hemophagocytic lymphohistiocytosis" post="(FHLH) [124], [125]. 8.3.1.5 Interferon-based therapy Interferons regulate the"/>
  <result pre="effective against COVID-19, especially in the early phase of the" exact="disease" post="[128]. In addition to the direct suppression of the"/>
  <result pre="Moreover, MSCs might improve ARDS, regenerate lung tissue, and lessen" exact="lung fibrosis" post="through secreting IL-10, vascular endothelial growth factor (VEGF), keratinocyte"/>
  <result pre="regenerate lung tissue, and lessen lung fibrosis through secreting IL-10," exact="vascular" post="endothelial growth factor (VEGF), keratinocyte growth factor (KGF), and"/>
  <result pre="return the T cell counts to a normal range, restore" exact="pulmonary" post="function, decrease the level of inflammatory cytokines, and increase"/>
  <result pre="known that cytokine-licensed MSCs were effective in preventing lipopolysaccharide (LPS)-induced" exact="acute" post="lung damage [134]. So, several clinical trials are being"/>
  <result pre="convalescent plasma therapy Plasma antibodies contribute to the elimination of" exact="infection" post="via directly binding to pathogens and neutralizing them, or"/>
  <result pre="(CP) is a passive-adaptive-immunotherapy applied to protect individuals from clinical" exact="infection" post="or prevent disease development. The early administration of CP"/>
  <result pre="passive-adaptive-immunotherapy applied to protect individuals from clinical infection or prevent" exact="disease" post="development. The early administration of CP or hyper-immune immunoglobulin"/>
  <result pre="hyper-immune immunoglobulin that contains high antibody titers could decrease the" exact="viral" post="load, reduce disease mortality, and shorten hospital stays [137],"/>
  <result pre="contains high antibody titers could decrease the viral load, reduce" exact="disease" post="mortality, and shorten hospital stays [137], [138]. While passive"/>
  <result pre="emergency treatment, especially in epidemics and pandemics, when there is" exact="limited" post="time or resources for pooled immunoglobulin preparation. Compared to"/>
  <result pre="a rapid immune-based therapy in the early stages of the" exact="disease" post="[140], to increase infected patients immunity against the virus,"/>
  <result pre="[141]. Moreover, plasma therapy can decrease viremia and reduce new" exact="infections" post="(through neutralizing antibodies), clear free virus and infected cells,"/>
  <result pre="cells, and alleviate the symptoms (like dry cough, fever, sputum," exact="muscle" post="pain) and pulmonary damage. Moreover, it can increase the"/>
  <result pre="the symptoms (like dry cough, fever, sputum, muscle pain) and" exact="pulmonary" post="damage. Moreover, it can increase the lymphocyte ratio and"/>
  <result pre="willing qualified donors, clinical conditions, eliminating host interactions, and the" exact="viral" post="kinetics of SARS-CoV-2, that will need to be solved"/>
  <result pre="of COVID-19 infection, including a negative follow-up molecular test, the" exact="absence of" post="symptoms, normal physical examination, and pre-donation screening assays. It"/>
  <result pre="[140]. It must be taken into account that transfusion-transmitted SARS-CoV-2," exact="acute" post="transfusion-related injuries, other transfusion-transmissible infections, transfusion-associated circulatory overload, and"/>
  <result pre="all of them showed a reduction in COVID-19 symptoms and" exact="viral" post="load, it is not yet clear that the antibodies"/>
  <result pre="and purity, high safety, and a low rate of blood-borne" exact="infections" post="that can overcome the limitations of intravenous immunoglobulins and"/>
  <result pre="membrane fusion, and sialic acid-binding sites), and reduce replication and" exact="infection" post="progression. Some mAbs that target the spike protein in"/>
  <result pre="in COVID-19 patient improvement. Besides, 47D11 could powerfully suppress the" exact="infection" post="of SARS-CoV and SARS-CoV-2 through an unknown mechanism [155]."/>
  <result pre="antibodies can be used as prophylactic or therapeutic agents against" exact="viral" post="infections [75]. For example, SAB-301 is a well-tolerated antiviral"/>
  <result pre="can be used as prophylactic or therapeutic agents against viral" exact="infections" post="[75]. For example, SAB-301 is a well-tolerated antiviral treatment"/>
  <result pre="is an effective immunomodulatory agent, which has been applied in" exact="autoimmune" post="and inflammatory diseases, bacterial infections, severe viral infections, fungal"/>
  <result pre="agent, which has been applied in autoimmune and inflammatory diseases," exact="bacterial infections," post="severe viral infections, fungal infections, and also in graft"/>
  <result pre="been applied in autoimmune and inflammatory diseases, bacterial infections, severe" exact="viral" post="infections, fungal infections, and also in graft versus host"/>
  <result pre="viral infections, fungal infections, and also in graft versus host" exact="disease" post="(GVHD). It is composed of polyclonal immunoglobulin G or"/>
  <result pre="against the virus [159]. IVIg has been used to treat" exact="infections" post="of the upper and lower respiratory tracts [160], [161]."/>
  <result pre="[159]. IVIg has been used to treat infections of the" exact="upper" post="and lower respiratory tracts [160], [161]. Besides, IVIg therapy"/>
  <result pre="has been used to treat infections of the upper and" exact="lower" post="respiratory tracts [160], [161]. Besides, IVIg therapy showed a"/>
  <result pre="been used to treat infections of the upper and lower" exact="respiratory" post="tracts [160], [161]. Besides, IVIg therapy showed a clinical"/>
  <result pre="of high-dose IVIg at the appropriate time point could prevent" exact="disease" post="progression to a severe state and enhance the patient"/>
  <result pre="Only eight (50%) of the 16 control patients had improved" exact="respiratory" post="status after 21Â days, of which one person was"/>
  <result pre="could increase the survival of patients with COVID-19 and improve" exact="respiratory" post="status, and may be an effective treatment [165]. 8.9"/>
  <result pre="proposed that NSAIDs could be considered for treating the emerging" exact="viral" post="illness in some cases, but most patients with COVID-19"/>
  <result pre="suggested that the use of ACE-I and ARB drugs for" exact="cardiovascular" post="indications could lead to an up-regulation of ACE2 receptors,"/>
  <result pre="the development of more severe COVID-19 [168]. However, the European" exact="Heart" post="Association as well as three major American cardiology bodies,"/>
  <result pre="However, the European Heart Association as well as three major" exact="American" post="cardiology bodies, including the American Heart Association, the American"/>
  <result pre="as well as three major American cardiology bodies, including the" exact="American" post="Heart Association, the American College of Cardiology, and the"/>
  <result pre="well as three major American cardiology bodies, including the American" exact="Heart" post="Association, the American College of Cardiology, and the Heart"/>
  <result pre="major American cardiology bodies, including the American Heart Association, the" exact="American" post="College of Cardiology, and the Heart Failure Society of"/>
  <result pre="American Heart Association, the American College of Cardiology, and the" exact="Heart Failure" post="Society of America, have all emphasized that patients who"/>
  <result pre="Heart Association, the American College of Cardiology, and the Heart" exact="Failure" post="Society of America, have all emphasized that patients who"/>
  <result pre="one and two clinical trials (2017), could significantly inhibit COVID-19" exact="infection" post="in the early stage and prevent the virus from"/>
  <result pre="for virus isolation) up to 1000â€&quot;5000 times (in terms of" exact="viral" post="load) in laboratory studies [169]. It must be mentioned"/>
  <result pre="stages of COVID-19. So, because SARS-CoV-2 can directly infect human" exact="blood vessels" post="and enter the kidneys, and hrsACE2 could prevent this"/>
  <result pre="further investigations are needed. 8.12 CRISPR Cas13 Clustered regularly interspaced" exact="short" post="palindromic repeats (CRISPR) is a novel genome engineering tool,"/>
  <result pre="Nitric oxide Newborns with severe ARDS, are treated with highâ€�dose" exact="pulmonary" post="surfactant, inhaled nitric oxide, highâ€�frequency oscillatory ventilation, and extracorporeal"/>
  <result pre="of Ivermectin to virus-infected Vero/hSLAM cells reduced the levels of" exact="viral" post="RNA by 5,000 times after 48-hour culture [178]. So,"/>
  <result pre="reducing injury in animal models with bleomycin-induced lung damage [182]." exact="Vitamin C" post="could also be effective in preventing COVID-19 as it"/>
  <result pre="in preventing COVID-19 as it can reduce the severity of" exact="lower" post="respiratory tract infections [183]. Moreover, It was suggested that"/>
  <result pre="preventing COVID-19 as it can reduce the severity of lower" exact="respiratory" post="tract infections [183]. Moreover, It was suggested that the"/>
  <result pre="as it can reduce the severity of lower respiratory tract" exact="infections" post="[183]. Moreover, It was suggested that the supplementation with"/>
  <result pre="29th 2020). Clinical trials Identifier Status country Tocilizumab inÂ COVID-19Â" exact="Pneumonia" post="NCT04317092 Recruiting Italy Evaluation of the Efficacy and Safety"/>
  <result pre="Recruiting China ACE Inhibitors, Angiotensin II Type-I Receptor Blockers, and" exact="Severity of" post="COVID-19 (CODIV-ACE) NCT04318418 Not yet recruiting Italy Treatment of"/>
  <result pre="yet recruiting The Use of Angiotensin-Converting Enzyme Inhibitors and Incident" exact="Respiratory" post="Infections, Are They Harmful or Protective? NCT04322786 Not yet"/>
  <result pre="Protective? NCT04322786 Not yet recruiting Nitric Oxide Gas Inhalation for" exact="Severe" post="Acute Respiratory Syndrome in COVID-19. NCT04290871 Withdrawn Proactive Prophylaxis"/>
  <result pre="NCT04322786 Not yet recruiting Nitric Oxide Gas Inhalation for Severe" exact="Acute" post="Respiratory Syndrome in COVID-19. NCT04290871 Withdrawn Proactive Prophylaxis With"/>
  <result pre="Not yet recruiting Nitric Oxide Gas Inhalation for Severe Acute" exact="Respiratory" post="Syndrome in COVID-19. NCT04290871 Withdrawn Proactive Prophylaxis With Azithromycin"/>
  <result pre="yet recruiting Nitric Oxide Gas Inhalation for Severe Acute Respiratory" exact="Syndrome" post="in COVID-19. NCT04290871 Withdrawn Proactive Prophylaxis With Azithromycin and"/>
  <result pre="NUTRIC Nutritional Risk Assessment Tool NCT04274322 Not yet recruiting Cohort" exact="Multiple" post="Randomized Controlled Trials Open-label of Immune Modulatory Drugs and"/>
  <result pre="yet recruiting France Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19" exact="Infection" post="and at Risk of Secondary Complication: a Prospective, Multicentre,"/>
  <result pre="Placebo in Patients Presenting COVID-19 Infection and at Risk of" exact="Secondary" post="Complication: a Prospective, Multicentre, Randomised, Double-blind Study NCT04325893 Not"/>
  <result pre="recruiting Xiyanping Injection for the Treatment of New Coronavirus Infected" exact="Pneumonia" post="NCT04275388 Not yet recruiting Chloroquine Diphosphate for the Treatment"/>
  <result pre="NCT04275388 Not yet recruiting Chloroquine Diphosphate for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Secondary to SARS-CoV2 NCT04323527 Recruiting Brazil"/>
  <result pre="Not yet recruiting Chloroquine Diphosphate for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Secondary to SARS-CoV2 NCT04323527 Recruiting Brazil Safety"/>
  <result pre="yet recruiting Chloroquine Diphosphate for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Secondary to SARS-CoV2 NCT04323527 Recruiting Brazil Safety and"/>
  <result pre="recruiting Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Secondary to SARS-CoV2 NCT04323527 Recruiting Brazil Safety and Immunogenicity"/>
  <result pre="Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome" exact="Secondary" post="to SARS-CoV2 NCT04323527 Recruiting Brazil Safety and Immunogenicity Study"/>
  <result pre="Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2" exact="Infection" post="NCT04283461 Recruiting United States Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)"/>
  <result pre="Coronavirus SARS-CoV2 Trial (COLCORONA) NCT04322682 Recruiting Canada Tocilizumab for SARS-CoV2" exact="Severe" post="Pneumonitis NCT04315480 Not yet recruiting Italy Efficacy and Safety"/>
  <result pre="SARS-CoV2 Trial (COLCORONA) NCT04322682 Recruiting Canada Tocilizumab for SARS-CoV2 Severe" exact="Pneumonitis" post="NCT04315480 Not yet recruiting Italy Efficacy and Safety of"/>
  <result pre="Efficacy and Safety of Darunavir and Cobicistat for Treatment of" exact="Pneumonia" post="Caused by 2019-nCoV NCT04252274 Recruiting China Treatment and Prevention"/>
  <result pre="Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV" exact="Infection" post="NCT04251871 Recruiting China COVIDL1: A Study to Investigate the"/>
  <result pre="A Study to Investigate the Efficacy of Tradipitant in Treating" exact="Severe" post="or Critical COVID-19 Infection NCT04326426 Not yet recruiting Nitric"/>
  <result pre="the Efficacy of Tradipitant in Treating Severe or Critical COVID-19" exact="Infection" post="NCT04326426 Not yet recruiting Nitric Oxide Gas Inhalation in"/>
  <result pre="Infection NCT04326426 Not yet recruiting Nitric Oxide Gas Inhalation in" exact="Severe" post="Acute Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States"/>
  <result pre="NCT04326426 Not yet recruiting Nitric Oxide Gas Inhalation in Severe" exact="Acute" post="Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States Inhaled"/>
  <result pre="Not yet recruiting Nitric Oxide Gas Inhalation in Severe Acute" exact="Respiratory" post="Syndrome in COVID-19 NCT04306393 Recruiting United States Inhaled Gaseous"/>
  <result pre="yet recruiting Nitric Oxide Gas Inhalation in Severe Acute Respiratory" exact="Syndrome" post="in COVID-19 NCT04306393 Recruiting United States Inhaled Gaseous Nitric"/>
  <result pre="Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and" exact="Viral" post="Lung (COVID-19) Infections NCT03331445 Active, not recruiting Canada NK"/>
  <result pre="(gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19)" exact="Infections" post="NCT03331445 Active, not recruiting Canada NK Cells Treatment for"/>
  <result pre="Active, not recruiting Canada NK Cells Treatment for Novel Coronavirus" exact="Pneumonia" post="NCT04280224 Recruiting China Evaluating and Comparing the Safety and"/>
  <result pre="Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus" exact="Infection" post="NCT04261907 Not yet recruiting A Pilot Clinical Study on"/>
  <result pre="Not yet recruiting A Pilot Clinical Study on Inhalation of" exact="Mesenchymal" post="Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia NCT04276987"/>
  <result pre="Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating" exact="Severe" post="Novel Coronavirus Pneumonia NCT04276987 Not yet recruiting Post-exposure Prophylaxis"/>
  <result pre="Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus" exact="Pneumonia" post="NCT04276987 Not yet recruiting Post-exposure Prophylaxis / Preemptive Therapy"/>
  <result pre="Recruiting United States STOP PIV - Phase III DAS181 Lower" exact="Tract" post="PIV Infection in Immunocompromised Subjects NCT03808922 Recruiting United States"/>
  <result pre="States STOP PIV - Phase III DAS181 Lower Tract PIV" exact="Infection" post="in Immunocompromised Subjects NCT03808922 Recruiting United States Norwegian Coronavirus"/>
  <result pre="Infection in Immunocompromised Subjects NCT03808922 Recruiting United States Norwegian Coronavirus" exact="Disease" post="2019 Study NCT04316377 Not yet recruiting Lessening Organ Dysfunction"/>
  <result pre="Coronavirus Disease 2019 Study NCT04316377 Not yet recruiting Lessening Organ" exact="Dysfunction" post="With VITamin C NCT03680274 Recruiting Canada Glucocorticoid Therapy for"/>
  <result pre="Recruiting Canada Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With" exact="Severe" post="Acute Respiratory Failure NCT04244591 Recruiting China Convalescent Plasma to"/>
  <result pre="Canada Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe" exact="Acute" post="Respiratory Failure NCT04244591 Recruiting China Convalescent Plasma to Limit"/>
  <result pre="Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute" exact="Respiratory" post="Failure NCT04244591 Recruiting China Convalescent Plasma to Limit Coronavirus"/>
  <result pre="Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory" exact="Failure" post="NCT04244591 Recruiting China Convalescent Plasma to Limit Coronavirus Associated"/>
  <result pre="Limit Coronavirus Associated Complications NCT04325672 Not yet recruiting United States" exact="Vitamin C" post="Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia"/>
  <result pre="recruiting United States Vitamin C Infusion for the Treatment of" exact="Severe" post="2019-nCoV Infected Pneumonia NCT04264533 Recruiting China Anti-il6 Treatment of"/>
  <result pre="Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected" exact="Pneumonia" post="NCT04264533 Recruiting China Anti-il6 Treatment of Serious COVID-19 Disease"/>
  <result pre="Infected Pneumonia NCT04264533 Recruiting China Anti-il6 Treatment of Serious COVID-19" exact="Disease" post="With Threatening Respiratory Failure Drug: RoActemra iv, RoActemra sc,"/>
  <result pre="Recruiting China Anti-il6 Treatment of Serious COVID-19 Disease With Threatening" exact="Respiratory" post="Failure Drug: RoActemra iv, RoActemra sc, Kevzara sc NCT04322773"/>
  <result pre="China Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory" exact="Failure" post="Drug: RoActemra iv, RoActemra sc, Kevzara sc NCT04322773 Not"/>
  <result pre="Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus" exact="Disease" post="(COVID-19) NCT04307693 Recruiting Korea Study to Evaluate the Safety"/>
  <result pre="Safety and Antiviral Activity of Remdesivir (GS-5734â&quot;¢) in Participants With" exact="Severe" post="Coronavirus Disease (COVID-19) NCT04292899 Recruiting United States NestCellÂ® Mesenchymal"/>
  <result pre="Antiviral Activity of Remdesivir (GS-5734â&quot;¢) in Participants With Severe Coronavirus" exact="Disease" post="(COVID-19) NCT04292899 Recruiting United States NestCellÂ® Mesenchymal Stem Cell"/>
  <result pre="With Severe Coronavirus Disease (COVID-19) NCT04292899 Recruiting United States NestCellÂ®" exact="Mesenchymal" post="Stem Cell to Treat Patients With Severe COVID-19 Pneumonia"/>
  <result pre="United States NestCellÂ® Mesenchymal Stem Cell to Treat Patients With" exact="Severe" post="COVID-19 Pneumonia (HOPE) NCT04315987 Not yet recruiting Bevacizumab in"/>
  <result pre="NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19" exact="Pneumonia" post="(HOPE) NCT04315987 Not yet recruiting Bevacizumab in Severe or"/>
  <result pre="Severe COVID-19 Pneumonia (HOPE) NCT04315987 Not yet recruiting Bevacizumab in" exact="Severe" post="or Critically Severe Patients With COVID-19 Pneumonia-RCT (BEST-RCT) NCT04305106"/>
  <result pre="(HOPE) NCT04315987 Not yet recruiting Bevacizumab in Severe or Critically" exact="Severe" post="Patients With COVID-19 Pneumonia-RCT (BEST-RCT) NCT04305106 Recruiting China The"/>
  <result pre="Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19)" exact="Pneumonia" post="NCT04273529 Not yet recruiting The Efficacy and Safety of"/>
  <result pre="NCT04273529 Not yet recruiting The Efficacy and Safety of Thalidomide" exact="Combined" post="With Low-dose Hormones in the Treatment of Severe COVID-19"/>
  <result pre="of Thalidomide Combined With Low-dose Hormones in the Treatment of" exact="Severe" post="COVID-19 NCT04273581 Not yet recruiting Treatment of COVID-19 Patients"/>
  <result pre="Wharton's Jelly-Mesenchymal Stem Cells NCT04313322 Recruiting Jordan Hydroxychloroquine Treatment for" exact="Severe" post="COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA) NCT04315896 Not yet"/>
  <result pre="Stem Cells NCT04313322 Recruiting Jordan Hydroxychloroquine Treatment for Severe COVID-19" exact="Pulmonary" post="Infection (HYDRA Trial) (HYDRA) NCT04315896 Not yet recruiting Tetrandrine"/>
  <result pre="Cells NCT04313322 Recruiting Jordan Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary" exact="Infection" post="(HYDRA Trial) (HYDRA) NCT04315896 Not yet recruiting Tetrandrine Tablets"/>
  <result pre="Treatment (SAC-COVID)v NCT04317040 Not yet recruiting United States Treatment With" exact="Mesenchymal" post="Stem Cells for Severe Corona Virus Disease 2019(COVID-19) NCT04288102"/>
  <result pre="yet recruiting United States Treatment With Mesenchymal Stem Cells for" exact="Severe" post="Corona Virus Disease 2019(COVID-19) NCT04288102 Recruiting China The Clinical"/>
  <result pre="United States Treatment With Mesenchymal Stem Cells for Severe Corona" exact="Virus Disease" post="2019(COVID-19) NCT04288102 Recruiting China The Clinical Study of Carrimycin"/>
  <result pre="States Treatment With Mesenchymal Stem Cells for Severe Corona Virus" exact="Disease" post="2019(COVID-19) NCT04288102 Recruiting China The Clinical Study of Carrimycin"/>
  <result pre="COVID-19(Methylprednisolone) NCT04273321 Recruiting China Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus" exact="Disease" post="(COVID-19) NCT04318444 Not yet recruiting United States Hydroxychloroquine Chemoprophylaxis"/>
  <result pre="Clinical Trial in 18â€&quot;60 Adults (APICTH)(vaccine) NCT04313127 Recruiting China Favipiravir" exact="Combined" post="With Tocilizumab in the Treatment of Corona Virus Disease"/>
  <result pre="China Favipiravir Combined With Tocilizumab in the Treatment of Corona" exact="Virus Disease" post="2019 NCT04310228 Recruiting China Novel Coronavirus Induced Severe Pneumonia"/>
  <result pre="Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus" exact="Disease" post="2019 NCT04310228 Recruiting China Novel Coronavirus Induced Severe Pneumonia"/>
  <result pre="Corona Virus Disease 2019 NCT04310228 Recruiting China Novel Coronavirus Induced" exact="Severe" post="Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells NCT04302519"/>
  <result pre="Virus Disease 2019 NCT04310228 Recruiting China Novel Coronavirus Induced Severe" exact="Pneumonia" post="Treated by Dental Pulp Mesenchymal Stem Cells NCT04302519 Not"/>
  <result pre="China Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp" exact="Mesenchymal" post="Stem Cells NCT04302519 Not yet recruiting Multicenter Clinical Study"/>
  <result pre="Safety of Xiyanping Injection in the Treatment of New Coronavirus" exact="Infection" post="Pneumonia (General and Severe) NCT04295551 Not yet recruiting Chloroquine"/>
  <result pre="of Xiyanping Injection in the Treatment of New Coronavirus Infection" exact="Pneumonia" post="(General and Severe) NCT04295551 Not yet recruiting Chloroquine Prevention"/>
  <result pre="and Severe) NCT04295551 Not yet recruiting Chloroquine Prevention of Coronavirus" exact="Disease" post="(COVID-19) in the Healthcare Setting (COPCOV) NCT04303507 Not yet"/>
  <result pre="recruiting Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets" exact="Combined" post="With Standard Treatment/ Standard Treatment in Patients With Suspected"/>
  <result pre="Standard Treatment in Patients With Suspected and Mild Novel Coronavirus" exact="Pneumonia" post="(COVID-19) NCT04273763 Enrolling by invitation China Yinhu Qingwen Decoction"/>
  <result pre="yet recruiting Tocilizumab vs. CRRT in Management of Cytokine Release" exact="Syndrome" post="(CRS) in COVID-19 (TACOS) NCT04306705 Recruiting China Mild/Moderate 2019-nCoV"/>
  <result pre="Hospitalization NCT04311177 Not yet recruiting United States Study of Human" exact="Umbilical" post="Cord Mesenchymal Stem Cells in the Treatment of Novel"/>
  <result pre="Not yet recruiting United States Study of Human Umbilical Cord" exact="Mesenchymal" post="Stem Cells in the Treatment of Novel Coronavirus Severe"/>
  <result pre="Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus" exact="Severe" post="Pneumonia NCT04273646 Not yet recruiting China Mesenchymal Stem Cell"/>
  <result pre="Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe" exact="Pneumonia" post="NCT04273646 Not yet recruiting China Mesenchymal Stem Cell Treatment"/>
  <result pre="of Novel Coronavirus Severe Pneumonia NCT04273646 Not yet recruiting China" exact="Mesenchymal" post="Stem Cell Treatment for Pneumonia Patients Infected With 2019"/>
  <result pre="NCT04273646 Not yet recruiting China Mesenchymal Stem Cell Treatment for" exact="Pneumonia" post="Patients Infected With 2019 Novel Coronavirus NCT04252118 Recruiting China"/>
  <result pre="NCT04252118 Recruiting China The Efficacy of Intravenous Immunoglobulin Therapy for" exact="Severe" post="2019-nCoV Infected Pneumonia NCT04261426 Not yet recruiting A Prospective/Retrospective,"/>
  <result pre="The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected" exact="Pneumonia" post="NCT04261426 Not yet recruiting A Prospective/Retrospective, Randomized Controlled Clinical"/>
  <result pre="Hydrochloride combined with Interferon atomization NCT04254874 recruiting China Bevacizumab in" exact="Severe" post="or Critical Patients With COVID-19 Pneumonia (BEST-CP) NCT04275414 recruiting"/>
  <result pre="recruiting China Bevacizumab in Severe or Critical Patients With COVID-19" exact="Pneumonia" post="(BEST-CP) NCT04275414 recruiting China A Randomized, Open, Controlled Clinical"/>
  <result pre="to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV" exact="Pneumonia" post="NCT04261270 recruiting China Intravenous Aviptadil for COVID-19 Associated Acute"/>
  <result pre="2019-nCoV Pneumonia NCT04261270 recruiting China Intravenous Aviptadil for COVID-19 Associated" exact="Acute" post="Respiratory Distress (COVID-AIV) NCT04311697 Not yet recruiting Israel The"/>
  <result pre="Pneumonia NCT04261270 recruiting China Intravenous Aviptadil for COVID-19 Associated Acute" exact="Respiratory" post="Distress (COVID-AIV) NCT04311697 Not yet recruiting Israel The Efficacy"/>
  <result pre="recruiting Israel The Efficacy of Different Hormone Doses in 2019-nCoV" exact="Severe" post="PneumoniaDrug: Methylprednisolone NCT04263402 recruiting China Nitric Oxide Gas Inhalation"/>
  <result pre="Treatment Trial (ACTT)Drug: Remdesivir NCT04280705 Recruiting United States Treatment of" exact="Pulmonary" post="Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng HuayuDrug: N-acetylcysteineÂ"/>
  <result pre="Recruiting United States Treatment of Pulmonary Fibrosis Due to 2019-nCoV" exact="Pneumonia" post="With Fuzheng HuayuDrug: N-acetylcysteineÂ +Â Fuzheng Huayu Tablet, N-acetylcysteineÂ"/>
  <result pre="Inhaled nitric oxide gas NCT04312243 Not yet recruiting Treatment of" exact="Acute" post="Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured PatientsDrug: Immunoglobulin"/>
  <result pre="nitric oxide gas NCT04312243 Not yet recruiting Treatment of Acute" exact="Severe" post="2019-nCoV Pneumonia With Immunoglobulin From Cured PatientsDrug: Immunoglobulin of"/>
  <result pre="gas NCT04312243 Not yet recruiting Treatment of Acute Severe 2019-nCoV" exact="Pneumonia" post="With Immunoglobulin From Cured PatientsDrug: Immunoglobulin of cured patients,"/>
  <result pre="Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of" exact="Pneumonia" post="Caused by Novel Coronavirus NCT04260594 Not yet recruiting Evaluation"/>
  <result pre="Novel Coronavirus NCT04260594 Not yet recruiting Evaluation of Ganovo (Danoprevir)" exact="Combined" post="With Ritonavir in the Treatment of Novel Coronavirus InfectionDrug:"/>
  <result pre="Completed China Eculizumab (Soliris) in Covid-19 Infected Patients NCT04288713 Available" exact="Severe" post="2019-nCoV Remdesivir RCT NCT04257656 Recruiting China nitric Oxide Gas"/>
  <result pre="Remdesivir RCT NCT04257656 Recruiting China nitric Oxide Gas Inhalation in" exact="Severe" post="Acute Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States"/>
  <result pre="RCT NCT04257656 Recruiting China nitric Oxide Gas Inhalation in Severe" exact="Acute" post="Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States Umbilical"/>
  <result pre="NCT04257656 Recruiting China nitric Oxide Gas Inhalation in Severe Acute" exact="Respiratory" post="Syndrome in COVID-19 NCT04306393 Recruiting United States Umbilical Cord(UC)-Derived"/>
  <result pre="Recruiting China nitric Oxide Gas Inhalation in Severe Acute Respiratory" exact="Syndrome" post="in COVID-19 NCT04306393 Recruiting United States Umbilical Cord(UC)-Derived Mesenchymal"/>
  <result pre="Severe Acute Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States" exact="Umbilical" post="Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(CoV)"/>
  <result pre="Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States Umbilical Cord(UC)-Derived" exact="Mesenchymal" post="Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(CoV) Pneumonia NCT04269525"/>
  <result pre="Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(CoV)" exact="Pneumonia" post="NCT04269525 Recruiting China Evaluating and Comparing the Safety and"/>
  <result pre="Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus" exact="Infection" post="NCT04261907 Not yet recruiting Vitamin C Infusion for the"/>
  <result pre="and Lopinavir/Ritonavir for Novel Coronavirus Infection NCT04261907 Not yet recruiting" exact="Vitamin C" post="Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia"/>
  <result pre="Not yet recruiting Vitamin C Infusion for the Treatment of" exact="Severe" post="2019-nCoV Infected Pneumonia NCT04264533 Recruiting China Expanded Access Remdesivir"/>
  <result pre="Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected" exact="Pneumonia" post="NCT04264533 Recruiting China Expanded Access Remdesivir (RDV; GS-5734â&quot;¢) NCT04302766"/>
  <result pre="Available Xiyanping Injection for the Treatment of New Coronavirus Infected" exact="Pneumonia" post="NCT04275388 Not yet recruiting Safety and Immunogenicity Study of"/>
  <result pre="and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2" exact="Infection" post="NCT04283461 recruiting United States Tocilizumab for SARS-CoV2 Severe Pneumonitis"/>
  <result pre="Prevent SARS-CoV-2 Infection NCT04283461 recruiting United States Tocilizumab for SARS-CoV2" exact="Severe" post="Pneumonitis NCT04315480 Not yet recruiting Italy Efficacy and Safety"/>
  <result pre="SARS-CoV-2 Infection NCT04283461 recruiting United States Tocilizumab for SARS-CoV2 Severe" exact="Pneumonitis" post="NCT04315480 Not yet recruiting Italy Efficacy and Safety of"/>
  <result pre="Efficacy and Safety of Darunavir and Cobicistat for Treatment of" exact="Pneumonia" post="Caused by 2019-nCoV NCT04252274 recruiting China Efficacy and Safety"/>
  <result pre="recruiting China Efficacy and Safety of Hydroxychloroquine for Treatment of" exact="Pneumonia" post="Caused by 2019-nCoV (HC-nCoV) NCT04261517 Completed China Treatment and"/>
  <result pre="of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV" exact="Pneumonia" post="NCT04275245 recruiting China Stem Cell Educator Therapy Treat the"/>
  <result pre="Pneumonia NCT04275245 recruiting China Stem Cell Educator Therapy Treat the" exact="Viral" post="Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2"/>
  <result pre="Stem Cell Educator Therapy Treat the Viral Inflammation Caused by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 NCT04299152 Not yet recruiting"/>
  <result pre="Cell Educator Therapy Treat the Viral Inflammation Caused by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 NCT04299152 Not yet recruiting NK"/>
  <result pre="Educator Therapy Treat the Viral Inflammation Caused by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 NCT04299152 Not yet recruiting NK Cells"/>
  <result pre="Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 NCT04299152 Not yet recruiting NK Cells Treatment"/>
  <result pre="NCT04299152 Not yet recruiting NK Cells Treatment for Novel Coronavirus" exact="Pneumonia" post="NCT04280224 Recruiting China Glucocorticoid Therapy for Novel CoronavirusCritically Ill"/>
  <result pre="Recruiting China Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With" exact="Severe" post="Acute Respiratory FailureDrug: methylprednisolone therapy NCT04244591 Recruiting China Norwegian"/>
  <result pre="China Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe" exact="Acute" post="Respiratory FailureDrug: methylprednisolone therapy NCT04244591 Recruiting China Norwegian Coronavirus"/>
  <result pre="Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute" exact="Respiratory" post="FailureDrug: methylprednisolone therapy NCT04244591 Recruiting China Norwegian Coronavirus Disease"/>
  <result pre="Acute Respiratory FailureDrug: methylprednisolone therapy NCT04244591 Recruiting China Norwegian Coronavirus" exact="Disease" post="2019 StudyDrug: Hydroxychloroquine Sulfate NCT04316377 Not yet recruiting Lopinavir/"/>
  <result pre="Recruiting United States A Pilot Clinical Study on Inhalation of" exact="Mesenchymal" post="Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia NCT04276987"/>
  <result pre="Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating" exact="Severe" post="Novel Coronavirus Pneumonia NCT04276987 Not yet recruiting Nitric Oxide"/>
  <result pre="Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus" exact="Pneumonia" post="NCT04276987 Not yet recruiting Nitric Oxide Gas Inhalation Therapy"/>
  <result pre="yet recruiting Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19" exact="Infection" post="NCT04290858 Withdrawn Nitric Oxide Gas Inhalation for Severe Acute"/>
  <result pre="Mild/Moderate COVID19 Infection NCT04290858 Withdrawn Nitric Oxide Gas Inhalation for" exact="Severe" post="Acute Respiratory Syndrome in COVID-19. NCT04290871 Withdrawn 10 Conclusion"/>
  <result pre="COVID19 Infection NCT04290858 Withdrawn Nitric Oxide Gas Inhalation for Severe" exact="Acute" post="Respiratory Syndrome in COVID-19. NCT04290871 Withdrawn 10 Conclusion In"/>
  <result pre="Infection NCT04290858 Withdrawn Nitric Oxide Gas Inhalation for Severe Acute" exact="Respiratory" post="Syndrome in COVID-19. NCT04290871 Withdrawn 10 Conclusion In conclusion,"/>
  <result pre="NCT04290858 Withdrawn Nitric Oxide Gas Inhalation for Severe Acute Respiratory" exact="Syndrome" post="in COVID-19. NCT04290871 Withdrawn 10 Conclusion In conclusion, SARS-CoV-2"/>
  <result pre="contagious virus, and there is no specific treatment for COVID-19" exact="disease" post="up to now. It must be taken into account"/>
  <result pre="concernThe Lancet.395102232020470473 3GuoY.-R.CaoQ.-D.HongZ.-S.TanY.-Y.ChenS.-D.JinH.-J.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;an update on the statusMil. Med. Res.71202011031928528"/>
  <result pre="Lancet Global Health.2020 7MohamedK.RodrÃ­guez-RomÃ¡nE.RahmaniF.ZhangH.IvanovskaM.MakkaS.A.Borderless collaboration is needed for COVID-19; a" exact="disease" post="that knows no bordersInfect Control Hosp Epidemiol2020 8MomtazmaneshS.OchsH.D.UddinL.Q.PercM.RoutesJ.M.Nuno VieiraD.All"/>
  <result pre="Control Hosp Epidemiol2020 8MomtazmaneshS.OchsH.D.UddinL.Q.PercM.RoutesJ.M.Nuno VieiraD.All together to Fight Novel Coronavirus" exact="Disease" post="(COVID-19)The American Journal of Tropical Medicine and Hygiene.2020 9HanaeiS.RezaeiN.COVID-19:"/>
  <result pre="Epidemiol2020 8MomtazmaneshS.OchsH.D.UddinL.Q.PercM.RoutesJ.M.Nuno VieiraD.All together to Fight Novel Coronavirus Disease (COVID-19)The" exact="American" post="Journal of Tropical Medicine and Hygiene.2020 9HanaeiS.RezaeiN.COVID-19: Developing from"/>
  <result pre="Res2020 10ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat originBioRxiv.2020 11WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.A"/>
  <result pre="its potential bat originBioRxiv.2020 11WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature5797798202026526932015508 12Zhou P, Yang X, Wang X,"/>
  <result pre="potential bat originBioRxiv.2020 11WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature5797798202026526932015508 12Zhou P, Yang X, Wang X, Hu"/>
  <result pre="X, Hu B, Zhang L, Zhang W, et al. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="2019 novel coronavirus outbreak in Wuhan, China. International Journal of" exact="Infectious" post="Diseases. 2020;91:264-6. 16ChenN.ZhouM.DongX.QuJ.GongF.HanY.Epidemiological and clinical characteristics of 99 cases"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyThe Lancet.395102232020507513 17CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features,"/>
  <result pre="A Review of the Current LiteratureEJMO.41202017 20LeungW.K.ToK.-fChanP.K.ChanH.L.WuA.K.LeeN.Enteric involvement of severe" exact="acute" post="respiratory syndrome-associated coronavirus infectionGastroenterology125420031011101714517783 21FanZ.ChenL.LiJ.ChengX.YangJ.TianC.Clinical Features of COVID-19-Related Liver"/>
  <result pre="Review of the Current LiteratureEJMO.41202017 20LeungW.K.ToK.-fChanP.K.ChanH.L.WuA.K.LeeN.Enteric involvement of severe acute" exact="respiratory" post="syndrome-associated coronavirus infectionGastroenterology125420031011101714517783 21FanZ.ChenL.LiJ.ChengX.YangJ.TianC.Clinical Features of COVID-19-Related Liver DamageClinical"/>
  <result pre="Epidemiology2020 23DongY.MoX.HuY.QiX.JiangF.JiangZ.Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus" exact="disease" post="in ChinaPediatrics2020 24Bi Q, Wu Y, Mei S, Ye"/>
  <result pre="cases and 1,286 of their close contacts. medRxiv. 2020. 25LuX.ZhangL.DuH.ZhangJ.LiY.Y.QuJ.SARS-CoV-2" exact="Infection" post="in ChildrenN. Engl. J. Med.2020 26JonesV.G.MillsM.SuarezD.HoganC.A.YehD.SegalJ.B.COVID-19 and Kawasaki disease:"/>
  <result pre="H, Santarpia GW, et al. Transmission Potential of SARS-CoV-2 in" exact="Viral" post="Shedding Observed at the University of Nebraska Medical Center."/>
  <result pre="Center. medRxiv. 2020. 30McIntosh K, Hirsch MS, Bloom A. Coronavirus" exact="disease" post="2019 (COVID-19). UpToDate Hirsch MS, Bloom A (Eds) Accessed"/>
  <result pre="MS, Bloom A (Eds) Accessed Mar. 2020;5. 31RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN. Engl. J. Med.2020"/>
  <result pre="from an asymptomatic contact in GermanyN. Engl. J. Med.2020 32YuP.ZhuJ.ZhangZ.HanY.HuangL.A" exact="familial" post="cluster of infection associated with the 2019 novel coronavirus"/>
  <result pre="contact in GermanyN. Engl. J. Med.2020 32YuP.ZhuJ.ZhangZ.HanY.HuangL.A familial cluster of" exact="infection" post="associated with the 2019 novel coronavirus indicating potential person-to-person"/>
  <result pre="Li L, et al. Time course of lung changes on" exact="chest" post="CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia."/>
  <result pre="Radiology. 2020:200370. 35ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="China: a retrospective cohort studyThe Lancet2020 36WuY.GuoC.TangL.HongZ.ZhouJ.DongX.Prolonged presence of SARS-CoV-2" exact="viral" post="RNA in faecal samples. The LancetGastroenterology &amp;amp; Hepatology.2020 37LanL.XuD.YeG.XiaC.WangS.LiY.Positive"/>
  <result pre="by RT-PCR in Stool Specimen from Asymptomatic Child, China. Emerging" exact="infectious diseases." post="2020;26(6). 39WangW.XuY.GaoR.LuR.HanK.WuG.Detection of SARS-CoV-2 in Different Types ofClinical Specimens."/>
  <result pre="J, Sheng X, et al. Lack of Vertical Transmission of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2, China. Emerging infectious diseases."/>
  <result pre="Sheng X, et al. Lack of Vertical Transmission of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2, China. Emerging infectious diseases. 2020;26(6)."/>
  <result pre="X, et al. Lack of Vertical Transmission of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2, China. Emerging infectious diseases. 2020;26(6). 42Network"/>
  <result pre="et al. Lack of Vertical Transmission of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2, China. Emerging infectious diseases. 2020;26(6). 42Network J."/>
  <result pre="Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerging" exact="infectious diseases." post="2020;26(6). 42Network J. Possible Vertical Transmission of SARS-CoV-2 From"/>
  <result pre="Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her" exact="Newborn" post="2020 March 26 [Available from: https://jamanetwork.com/journals/jama/fullarticle/2763853. 43Network J. Antibodies"/>
  <result pre="43Network J. Antibodies in Infants Born to Mothers With COVID-19" exact="Pneumonia" post="2020 March 26 [Available from: https://jamanetwork.com/journals/jama/fullarticle/2763854. 44PeeriN.C.ShresthaN.RahmanM.S.ZakiR.TanZ.BibiS.The SARS, MERS"/>
  <result pre="- 11 March 2020 2020March 11 [Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. 53uvex." exact="Respiratory" post="protection 2020 March 30 [Available from: https://www.uvex.co.za/en/products/respiratory-protection/. 54ecdc. Cloth"/>
  <result pre="Eurosurveillance. 2020;25(3). 58MorrowE.S.RoseweirA.EdwardsJ.The role of gamma delta T lymphocytes in" exact="breast" post="cancer: a reviewTranslational Research.2032019889630194922 59SaghazadehA.RezaeiN.Towards treatment planning of COVID-19:"/>
  <result pre="21 [Available from: https://covid19treatmentguidelines.nih.gov/introduction/. 62RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseThe lancet.395102232020e30e31 63WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients"/>
  <result pre="[Available from: https://covid19treatmentguidelines.nih.gov/introduction/. 62RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseThe lancet.395102232020e30e31 63WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with"/>
  <result pre="63WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan2020ChinaJama 64Li H, Wang Y, Xu J, Cao"/>
  <result pre="za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of" exact="tuberculosis" post="and respiratory diseases. 2020;43:E002-E. 65WuC.ChenX.CaiY.ZhouX.XuS.HuangH.Risk factors associated with acute"/>
  <result pre="Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and" exact="respiratory" post="diseases. 2020;43:E002-E. 65WuC.ChenX.CaiY.ZhouX.XuS.HuangH.Risk factors associated with acute respiratory distress"/>
  <result pre="of tuberculosis and respiratory diseases. 2020;43:E002-E. 65WuC.ChenX.CaiY.ZhouX.XuS.HuangH.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="tuberculosis and respiratory diseases. 2020;43:E002-E. 65WuC.ChenX.CaiY.ZhouX.XuS.HuangH.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="respiratory diseases. 2020;43:E002-E. 65WuC.ChenX.CaiY.ZhouX.XuS.HuangH.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan2020ChinaJAMA internal medicine 66Li H, Wang"/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan2020ChinaJAMA internal medicine 66Li H, Wang Y, Xu"/>
  <result pre="za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of" exact="tuberculosis" post="and respiratory diseases. 2020;43:E002. 67De Clercq E. New Nucleoside"/>
  <result pre="Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and" exact="respiratory" post="diseases. 2020;43:E002. 67De Clercq E. New Nucleoside Analogues for"/>
  <result pre="67De Clercq E. New Nucleoside Analogues for the Treatment of" exact="Hemorrhagic" post="Fever Virus Infections. Chemistryâ€&quot;An Asian Journal. 2019;14(22):3962-8. 68OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment"/>
  <result pre="Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic" exact="Fever" post="Virus Infections. Chemistryâ€&quot;An Asian Journal. 2019;14(22):3962-8. 68OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of"/>
  <result pre="Infections. Chemistryâ€&quot;An Asian Journal. 2019;14(22):3962-8. 68OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of advanced Ebola" exact="virus infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172124583123"/>
  <result pre="Chemistryâ€&quot;An Asian Journal. 2019;14(22):3962-8. 68OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172124583123"/>
  <result pre="and Interferon Therapy for Critically Ill Patients With Middle East" exact="Respiratory" post="Syndrome: A Multicenter Observational StudyClin. Infect. Dis.2019 74ElfikyA.A.Anti-HCV, nucleotide"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discovery6120201431934347 78(FDA) FaDA. Coronavirus (COVID-19) Update: FDA"/>
  <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
  <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCRJ. Korean Med. Sci.2020;35(6). 82CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial"/>
  <result pre="84ChenL.GuiC.LuoX.YangQ.GÃ¼ntherS.ScandellaE.Cinanserin is an inhibitor of the 3C-like proteinase of severe" exact="acute" post="respiratory syndrome coronavirus and strongly reduces virus replication in"/>
  <result pre="is an inhibitor of the 3C-like proteinase of severe acute" exact="respiratory" post="syndrome coronavirus and strongly reduces virus replication in vitroJ."/>
  <result pre="an inhibitor of the 3C-like proteinase of severe acute respiratory" exact="syndrome" post="coronavirus and strongly reduces virus replication in vitroJ. Virol.791120057095710315890949"/>
  <result pre="candidatesChemRxiv2020 90ParkJ.-Y.JeongH.J.KimJ.H.KimY.M.ParkS.-J.KimD.Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirusBiol. Pharm. Bull.2012b1200623 91Elfiky AA, Ibrahim NS."/>
  <result pre="90ParkJ.-Y.JeongH.J.KimJ.H.KimY.M.ParkS.-J.KimD.Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirusBiol. Pharm. Bull.2012b1200623 91Elfiky AA, Ibrahim NS. Anti-SARS"/>
  <result pre="from Alnus japonica inhibit papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirusBiol. Pharm. Bull.2012b1200623 91Elfiky AA, Ibrahim NS. Anti-SARS and"/>
  <result pre="Newly Emerged Coronavirus (2019-nCoV). 2020. 92DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics.1412020586032147628 93AryaR.DasA.PrasharV.KumarM.Potential inhibitors against papain-like"/>
  <result pre="a clinically proven protease inhibitorCell2020 96MeulemanP.AlbeckaA.BelouzardS.VercauterenK.VerhoyeL.WychowskiC.Griffithsin has antiviral activity against" exact="hepatitis C" post="virusAntimicrob. Agents Chemother.551120115159516721896910 97MoriT.O'KeefeB.R.SowderR.C.BringansS.GardellaR.BergS.Isolation and characterization of griffithsin, a"/>
  <result pre="Drug Resistance.83201845946430396013 101VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirology journal.2120056916115318 102GoldenE.B.ChoH.-Y.HofmanF.M.LouieS.G.SchÃ¶nthalA.H.ChenT.C.Quinoline-based antimalarial drugs: a novel class"/>
  <result pre="[Available from: https://www.clinicaltrialsarena.com/news/coronavirus-covid-19-choroquine-data/. 106McChesneyE.W.Animal toxicity and pharmacokinetics of hydroxychloroquine sulfateThe" exact="American" post="journal of medicine.751198311186408923 107WenigerH.OrganizationW.H.Review of side effects and toxicity"/>
  <result pre="chloroquine1979World health OrganizationGeneva 108LaaksonenA.-L.KoskiahdeV.JuvaK.Dosage of antimalarial drugs for children with" exact="juvenile rheumatoid arthritis" post="and systemic lupus erythematosus: a clinical study with determination"/>
  <result pre="health OrganizationGeneva 108LaaksonenA.-L.KoskiahdeV.JuvaK.Dosage of antimalarial drugs for children with juvenile" exact="rheumatoid arthritis" post="and systemic lupus erythematosus: a clinical study with determination"/>
  <result pre="OrganizationGeneva 108LaaksonenA.-L.KoskiahdeV.JuvaK.Dosage of antimalarial drugs for children with juvenile rheumatoid" exact="arthritis" post="and systemic lupus erythematosus: a clinical study with determination"/>
  <result pre="of antimalarial drugs for children with juvenile rheumatoid arthritis and" exact="systemic" post="lupus erythematosus: a clinical study with determination of serum"/>
  <result pre="antimalarial drugs for children with juvenile rheumatoid arthritis and systemic" exact="lupus" post="erythematosus: a clinical study with determination of serum concentrations"/>
  <result pre="storm and immunopathology. Seminars in immunopathology2017Springer 112CameronM.J.Bermejo-MartinJ.F.DaneshA.MullerM.P.KelvinD.J.Human immunopathogenesis of severe" exact="acute" post="respiratory syndrome (SARS)Virus Res.13312008131917374415 113MinC.-K.CheonS.HaN.-Y.SohnK.M.KimY.AigerimA.Comparative and kinetic analysis of"/>
  <result pre="and immunopathology. Seminars in immunopathology2017Springer 112CameronM.J.Bermejo-MartinJ.F.DaneshA.MullerM.P.KelvinD.J.Human immunopathogenesis of severe acute" exact="respiratory" post="syndrome (SARS)Virus Res.13312008131917374415 113MinC.-K.CheonS.HaN.-Y.SohnK.M.KimY.AigerimA.Comparative and kinetic analysis of viral"/>
  <result pre="immunopathology. Seminars in immunopathology2017Springer 112CameronM.J.Bermejo-MartinJ.F.DaneshA.MullerM.P.KelvinD.J.Human immunopathogenesis of severe acute respiratory" exact="syndrome" post="(SARS)Virus Res.13312008131917374415 113MinC.-K.CheonS.HaN.-Y.SohnK.M.KimY.AigerimA.Comparative and kinetic analysis of viral shedding"/>
  <result pre="acute respiratory syndrome (SARS)Virus Res.13312008131917374415 113MinC.-K.CheonS.HaN.-Y.SohnK.M.KimY.AigerimA.Comparative and kinetic analysis of" exact="viral" post="shedding and immunological responses in MERS patients representing a"/>
  <result pre="immunological responses in MERS patients representing a broad spectrum of" exact="disease" post="severitySci. Rep.61201611228442746 114He J, Tao H, Yan Y, Huang"/>
  <result pre="Huang S-Y, Xiao Y. Molecular mechanism of evolution and human" exact="infection" post="with the novel coronavirus (2019-nCoV). bioRxiv. 2020. 115LiuT.ZhangJ.YangY.ZhangL.MaH.LiZ.The potential"/>
  <result pre="GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirusBioRxiv.2020 117XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of"/>
  <result pre="T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirusBioRxiv.2020 117XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19"/>
  <result pre="of a new coronavirusBioRxiv.2020 117XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeThe Lancet respiratory medicine.84202042042232085846 118Liu Y, Sun"/>
  <result pre="a new coronavirusBioRxiv.2020 117XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeThe Lancet respiratory medicine.84202042042232085846 118Liu Y, Sun W,"/>
  <result pre="findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet" exact="respiratory" post="medicine.84202042042232085846 118Liu Y, Sun W, Li J, Chen L,"/>
  <result pre="Y, Zhang L, et al. Clinical features and progression of" exact="acute" post="respiratory distress syndrome in coronavirus disease 2019. MedRxiv. 2020."/>
  <result pre="Zhang L, et al. Clinical features and progression of acute" exact="respiratory" post="distress syndrome in coronavirus disease 2019. MedRxiv. 2020. 119BarrettD.M.TeacheyD.T.GruppS.A.Toxicity"/>
  <result pre="et al. Clinical features and progression of acute respiratory distress" exact="syndrome" post="in coronavirus disease 2019. MedRxiv. 2020. 119BarrettD.M.TeacheyD.T.GruppS.A.Toxicity management for"/>
  <result pre="features and progression of acute respiratory distress syndrome in coronavirus" exact="disease" post="2019. MedRxiv. 2020. 119BarrettD.M.TeacheyD.T.GruppS.A.Toxicity management for patients receiving novel"/>
  <result pre="prolonged, reversible hyaluronan synthesisMatrix Biol.802019142829933044 122CollumS.D.ChenN.Y.HernandezA.M.HanmandluA.SweeneyH.MertensT.C.Inhibition of hyaluronan synthesis attenuates" exact="pulmonary" post="hypertension associated with lung fibrosisBr. J. Pharmacol.1741920173284330128688167 123MaschalidiS.SepulvedaF.E.GarrigueA.FischerA.de SaintBasile"/>
  <result pre="reversible hyaluronan synthesisMatrix Biol.802019142829933044 122CollumS.D.ChenN.Y.HernandezA.M.HanmandluA.SweeneyH.MertensT.C.Inhibition of hyaluronan synthesis attenuates pulmonary" exact="hypertension" post="associated with lung fibrosisBr. J. Pharmacol.1741920173284330128688167 123MaschalidiS.SepulvedaF.E.GarrigueA.FischerA.de SaintBasile G.Therapeutic"/>
  <result pre="SaintBasile G.Therapeutic effect of JAK1/2 blockade on the manifestations of" exact="hemophagocytic lymphohistiocytosis" post="in miceBlood, The Journal of the American Society of"/>
  <result pre="manifestations of hemophagocytic lymphohistiocytosis in miceBlood, The Journal of the" exact="American" post="Society of Hematology.128120166071 124JordanM.B.HildemanD.KapplerJ.MarrackP.An animal model of hemophagocytic lymphohistiocytosis"/>
  <result pre="of the American Society of Hematology.128120166071 124JordanM.B.HildemanD.KapplerJ.MarrackP.An animal model of" exact="hemophagocytic lymphohistiocytosis" post="(HLH): CD8+ T cells and interferon gamma are essential"/>
  <result pre="Erp EA, Luytjes W, Ferwerda G, Van Kasteren PB. Fc-Mediated" exact="Antibody" post="Effector Functions During Respiratory Syncytial Virus Infection and Disease."/>
  <result pre="Ferwerda G, Van Kasteren PB. Fc-Mediated Antibody Effector Functions During" exact="Respiratory" post="Syncytial Virus Infection and Disease. Frontiers in immunology. 2019;10."/>
  <result pre="Kasteren PB. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus" exact="Infection" post="and Disease. Frontiers in immunology. 2019;10. 136Gunn BM, Yu"/>
  <result pre="microbe. 2018;24(2):221-33. e5. 137YehK.-M.ChiuehT.-S.SiuL.LinJ.-C.ChanP.K.PengM.-Y.Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospitalJ."/>
  <result pre="2018;24(2):221-33. e5. 137YehK.-M.ChiuehT.-S.SiuL.LinJ.-C.ChanP.K.PengM.-Y.Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospitalJ. Antimicrob."/>
  <result pre="e5. 137YehK.-M.ChiuehT.-S.SiuL.LinJ.-C.ChanP.K.PengM.-Y.Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospitalJ. Antimicrob. Chemother.565200591992216183666"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ."/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ. Infect. Dis.21112015809025030060"/>
  <result pre="patients in Hong Kong. European Journal of Clinical Microbiology and" exact="Infectious" post="Diseases. 2005;24(1):44-6. 141Law PK. Emergent Serum Therapy and Antibody"/>
  <result pre="and Infectious Diseases. 2005;24(1):44-6. 141Law PK. Emergent Serum Therapy and" exact="Antibody" post="Medicine to Counteract Sudden Attacks of COVID-19 and Other"/>
  <result pre="of therapeutic agents for the treatment of the Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV)Travel Med. Infect. Dis.30201991831252170 159JawharaS.Could intravenous immunoglobulin"/>
  <result pre="therapeutic agents for the treatment of the Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV)Travel Med. Infect. Dis.30201991831252170 159JawharaS.Could intravenous immunoglobulin collected"/>
  <result pre="J. Mol. Sci.21720202272 160De RanieriD.FennyN.S.Intravenous immunoglobulin in the treatment of" exact="primary" post="immunodeficiency diseasesPediatr. Ann.4612017e8e1228079912 161GaleottiC.KaveriS.V.BayryJ.IVIG-mediated effector functions in autoimmune and"/>
  <result pre="Mol. Sci.21720202272 160De RanieriD.FennyN.S.Intravenous immunoglobulin in the treatment of primary" exact="immunodeficiency" post="diseasesPediatr. Ann.4612017e8e1228079912 161GaleottiC.KaveriS.V.BayryJ.IVIG-mediated effector functions in autoimmune and inflammatory"/>
  <result pre="treatment of primary immunodeficiency diseasesPediatr. Ann.4612017e8e1228079912 161GaleottiC.KaveriS.V.BayryJ.IVIG-mediated effector functions in" exact="autoimmune" post="and inflammatory diseasesInt. Immunol.2911201749149828666326 162WangJ.-T.ShengW.-H.FangC.-T.ChenY.-C.WangJ.-L.YuC.-J.Clinical manifestations, laboratory findings, and"/>
  <result pre="course and outcomes of critically ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infectionAnn. Intern. Med.1606201438939724474051 164CaoW.LiuX.BaiT.FanH.HongK.SongH.editors. High-dose intravenous immunoglobulin"/>
  <result pre="and outcomes of critically ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infectionAnn. Intern. Med.1606201438939724474051 164CaoW.LiuX.BaiT.FanH.HongK.SongH.editors. High-dose intravenous immunoglobulin as"/>
  <result pre="immunoglobulin as a therapeutic option for deteriorating patients with coronavirus" exact="disease" post="2019. Open forum infectious diseases2020Oxford University Press US 165CavalliG.De"/>
  <result pre="option for deteriorating patients with coronavirus disease 2019. Open forum" exact="infectious" post="diseases2020Oxford University Press US 165CavalliG.De LucaG.CampochiaroC.Della-TorreE.RipaM.CanettiD.Interleukin-1 blockade with high-dose"/>
  <result pre="165CavalliG.De LucaG.CampochiaroC.Della-TorreE.RipaM.CanettiD.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19," exact="acute" post="respiratory distress syndrome, and hyperinflammation: a retrospective cohort study."/>
  <result pre="LucaG.CampochiaroC.Della-TorreE.RipaM.CanettiD.Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute" exact="respiratory" post="distress syndrome, and hyperinflammation: a retrospective cohort study. The"/>
  <result pre="scientists. British Medical Journal Publishing Group; 2020. 168FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?"/>
  <result pre="Medical Journal Publishing Group; 2020. 168FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection? The LancetRespir. Med.2020"/>
  <result pre="risk for COVID-19 infection? The LancetRespir. Med.2020 169MonteilV.KwonH.PradoP.HagelkrÃ¼ysA.WimmerR.A.StahlM.Inhibition of SARS-CoV-2" exact="infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell2020"/>
  <result pre="Molecular cell. 2017;65(4):618-30. e7. 172GootenbergJ.S.AbudayyehO.O.LeeJ.W.EssletzbichlerP.DyA.J.JoungJ.Nucleic acid detection with CRISPR-Cas13a/C2c2Science3566336201743844228408723 173LuQ.ShiY.Coronavirus" exact="disease" post="(COVID-19) and neonate: What neonatologist need to knowJ. Med."/>
  <result pre="breathing patients with COVID-19. medRxiv. 2020. 175OrganizationW.H.Clinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected: interim"/>
  <result pre="patients with COVID-19. medRxiv. 2020. 175OrganizationW.H.Clinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected: interim guidance,"/>
  <result pre="with COVID-19. medRxiv. 2020. 175OrganizationW.H.Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected: interim guidance, 13"/>
  <result pre="175OrganizationW.H.Clinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected: interim guidance, 13 March 20202020World Health Organization"/>
  <result pre="methotrexate, colchicine, and other immunomodulatory drugs in the treatment of" exact="primary" post="biliary cirrhosis. Seminars in liver disease; 1997: Â© 1997"/>
  <result pre="drugs in the treatment of primary biliary cirrhosis. Seminars in" exact="liver disease;" post="1997: Â© 1997 by Thieme Medical Publishers, Inc. 181(WHO)"/>
  <result pre="[Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. 182NagaiA.MatsumiyaH.HayashiM.YasuiS.OkamotoH.KonnoK.Effects of nicotinamide and niacin on bleomycin-induced" exact="acute" post="injury and subsequent fibrosis in hamster lungsExp. Lung Res.20419942632817527336"/>
  <result pre="fibrosis in hamster lungsExp. Lung Res.20419942632817527336 183HemilÃ¤H.Vitamin C intake and" exact="susceptibility to" post="the common coldBr. J. Nutr.771199759729059230 184Wang L-s, Wang Y-r,"/>
  <result pre="Agents. 2020:105948. 185London IC. Report 13: Estimating the number of" exact="infections" post="and the impact of non-pharmaceutical interventions on COVID-19 in"/>
 </snippets>
</snippetsTree>
